Charles River Laboratories International, Inc. (NYSE:CRL) Receives $209.46 Consensus Price Target from Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $209.4615.

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. TD Cowen reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research report on Thursday. Robert W. Baird set a $224.00 price objective on shares of Charles River Laboratories International in a research report on Friday, January 9th. Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Evercore ISI upped their target price on Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors and hedge funds have recently modified their holdings of CRL. Tema Etfs LLC acquired a new stake in Charles River Laboratories International in the 4th quarter worth about $26,000. Cromwell Holdings LLC boosted its stake in shares of Charles River Laboratories International by 542.9% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after buying an additional 152 shares during the period. Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International during the second quarter worth approximately $29,000. Rothschild Investment LLC increased its stake in Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares during the period. Finally, Atlantic Union Bankshares Corp acquired a new position in Charles River Laboratories International in the 3rd quarter valued at $31,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $219.77 on Friday. The company has a market cap of $10.82 billion, a PE ratio of -140.88, a price-to-earnings-growth ratio of 6.57 and a beta of 1.61. The firm has a 50-day moving average of $196.95 and a 200-day moving average of $176.53. Charles River Laboratories International has a one year low of $91.86 and a one year high of $228.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. Charles River Laboratories International’s quarterly revenue was down .5% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.59 EPS. As a group, equities analysts forecast that Charles River Laboratories International will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.